Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Orexo AB Enters into Research Agreement with AstraZeneca PLC for Respiratory Disease Program


Friday, 25 Jan 2013 02:40am EST 

Orexo AB (Orexo) announced that it has entered into an agreement with AstraZeneca PLC (AstraZeneca) regarding OX-CLI, a preclinical program for a potential treatment of respiratory diseases. Under this agreement, Orexo grants to AstraZeneca rights to conduct further preclinical research and evaluation of compounds in Orexo’s OX-CLI program. AstraZeneca also has an option to acquire the compounds pertaining to the program subject to a full asset transfer agreement being executed by the parties, under which Orexo will receive development milestones and royalties on future revenues. 

Company Quote

4555.5
39.0 +0.86%
24 Dec 2014